Reading the tape
NASDAQ: RVMD
Revolution Medicines, Inc.
Healthcare · Biotechnology
Market Cap
$31.44B
52w High
$155.70
52w Low
$34.00
P/E
-24.86
Volume
2.40M
Outstanding Shares
212.59M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 271.61%FCF (TTM): -60.94%
What changed
The stock rose 271.61% over the last year. Free cash flow declined 60.94% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers.
CEOMark A. Goldsmith
SectorHealthcare
IndustryBiotechnology
Employees616
IPO dateFeb 13, 2020
Valuation
Forward P/E—
EV/EBITDA-13.68
Enterprise value$14.92B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-69.35%▼161.78%vs FY2024
Analyst consensus
RatingBuy
Target price$154.80▲4.67%
21
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$1.83 · Revenue est $2.43M
View